Summary
A significant myeloprotective effect of melatonin in mice treated with etoposide, cyclophosphamide or carboplatin has been reported. The present study was designed to evaluate if the same effect could be observed in patients receiving chemotherapy. Twenty previously untreated patients with inoperable lung cancer received two cycles of carboplatin (given at area under the curve 5 by the Calvert formula) on day 1 and etoposide (150 mg m–2 i.v.) on days 1–3 every 4 weeks. Melatonin 40 mg or placebo (double-blind) was given orally in the evening for 21 consecutive days, starting 2 days before chemotherapy. Patients were randomized to receive melatonin either with the first or the second cycle. Complete blood cell count with differential was done three times per week for 3 weeks. The median age of the cohort was 60 years (range 42–69), 16 patients had non-small cell and four patients small-cell lung cancer, 12 stage III and eight stage IV disease. In a multivariate analysis including age, sex, diagnosis, stage, performance status, doses of carboplatin and etoposide, and concomitant treatment with melatonin or placebo, the haematological parameters – depth and duration of toxicity for haemoglobin, platelets and neutrophils (ANC) – were not significantly different between cycles with/without melatonin. The mean ANC nadir and the mean number of days with ANC < 0.5 × 109 l–1 were 0.5 × 109 l–1 and 2.5 days, respectively, with/without melatonin. We concluded that, in patients with lung cancer, melatonin given orally at a dose of 40 mg per day for 21 days in the evening, does not protect against the myelotoxic effect of carboplatin and etoposide.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aldeghi, R., Lissoni, P., Barni, S., Ardizzoia, A., Tancini, G., Piperno, A., Pozzi, M., Ricci, G., Conti, A. & Maestroni, G. J. M. (1994). Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 30A: 167–170.
Aldhous, M., Franey, C., Wright, J. & Arendt, J. (1985). Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 19: 517–521.
Arendt, J. (1996). Melatonin. Br Med J 312: 1242–1243.
Brzezinski, A. (1997). Melatonin in humans. N Engl J Med 336: 186–195.
Canellos, G. P. (1994). High-dose therapy: here to stay or just visiting? J Clin Oncol 12: 5–6.
Capizzi, R. L., Scheffler, B. J. & Schein, P. S. (1993). Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72: 3495–3501.
Crinò, L., Clerici, M., Figoli, F., Carlini, P., Ceci, G., Cortesi, E., Carpi, A., Santini, A., Di Costanzo, F., Boni, C., Meacci, M., Corgna, E., Darwish, S., Scarcella, L., Santucci, A., Ballatori, E. & Tonato, M. (1995). Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 6: 347–353.
Genevay, M. C., Mormont, C., Thomas, F. & Berthier, R. (1996). The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654). Exp Hematol 24: 77–81.
Gurney, H., Dodwell, D., Thatcher, N. & Tattersall, M. H. N. (1993). Escalating drug delivery in cancer chemotherapy: A review of concepts and practice – part 1. Ann Oncol 4: 23–34.
Ihde, D. C. (1992). Chemotherapy of lung cancer. N Engl J Med 327: 1434–1441.
Jelinek, J., Fairbairn, L. J., Dexter, T. M., Rafferty, J. A., Stocking, C., Ostertag, W. & Margison, G. P. (1996). Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human 06-alkylguanine-DNA-alkyltransferase. Blood 87: 1957–1961.
Lissoni, P., Barni, S., Crispino, S., Tancini, G. & Fraschini, F. (1989). Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 25: 789–795.
Lissoni, P., Tisi, E., Barni, S., Ardizzoia, A., Rovelli, F., Rescaldani, R., Ballabio, D., Benenti, C., Angeli, M., Tancini, G., Conti, A. & Maestroni, G. J. M. (1992). Biological and clinical results of a neuroimmunotherapy with inteleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer 66: 155–158.
Lissoni, P., Barni, S., Tancini, G., Ardizzoia, A., Ricci, G., Aldeghi, R., Brivio, F., Tisi, E., Rovelli, F., Rescaldani, R., Quadro, G. & Maestroni, G. (1994). A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69: 196–199.
Machin, D. & Campbell, M. J. (1987). Statistical tables for the design of clinical trials. Blackwell Scientific Publications: Oxford.
Maestroni, G. J., Conti, A. & Lissoni, P. (1994a). Colony-stimulating activity and hemopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 54: 4740–4743.
Maestroni, G. J., Covacci, V. & Conti, A. (1994b). Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumour-bearing mice. Cancer Res 54: 2429–2432.
Maestroni, J. M., Hertens, E., Galli, P., Conti, A. & Pedrinis, E. (1996). Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin. J Pineal Res 21: 131–139.
Neri, B., Fiorelli, C., Moroni, F., Nicita, G., Paoletti, M. C., Ponchietti, R., Raugei, A., Santoni, G., Trippitelli, A. & Grechi, G. (1994). Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. Cancer 73: 3015–3019.
Stata Corp (1997). Stata Statistical Software. Stata corporation: (Abstract)
Waldhauser, F., Waldhauser, M., Lieberman, H. R., Deng, M-H, Linch, D. & Wurtman, R. J. (1984). Bioavailability of melatonin in humans. Neuroendocrinology 39: 307–313.
Author information
Authors and Affiliations
Additional information
Presented in part at the annual meeting of the American Society of Clinical Oncology 1997
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ghielmini, M., Pagani, O., Jong, J. et al. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer 80, 1058–1061 (1999). https://doi.org/10.1038/sj.bjc.6690463
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690463
